PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AZ’s long-acting COVID-19 antibody moves into phase III

AstraZeneca’s long-acting antibody (LAAB) combination AZD7442 for the treatment of COVID-19 is set to advance in two phase III clinical trials in the next few weeks.

The trials will involve over 6,000 participants at sites in and outside the US and will evaluate AZD7442 as a preventative COVID-19 treatment.

One trial is set to test the safety and efficacy of the LAAB to prevent infection for up to 12 months in approximately 5,000 participants. The second trial will evaluate post-exposure prophylaxis and pre-emptive treatment in around 1,100 participants.

AZ is also planning additional trials to evaluate AZD7442 in approximately 4,000 patients for the treatment of COVID-19.

AZD7442 was engineered using AZ’s proprietary half-life extension technology to increase the durability of the therapy for six to 12 months following the first administration.

By combining two LAABs, AZ is hoping that AZD7442 can reduce the risk of resistance developed by the SARS-CoV-2, which causes COVID-19.

Under an agreement with the US government’s Biomedical Advanced Research and Development Authority (BARDA), AZ has received support of approximately $486m for the development and supply of AZD7442.

AZ plans to supply up to 100,000 doses of AZD7442 beginning at the end of 2020, with the US government able to acquire up to an additional one million doses in 2021 under a separate agreement.

“This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating COVID-19 infections,” said Pascal Soriot, chief executive officer of AZ.

“We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalisation, with a focus on helping the most vulnerable people,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026